Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 2/20 | 0.39 |
| ▸ | ADH1C | P00326 | 2/20 | 0.39 |
| ▸ | ADH1A | P07327 | 2/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13953119 | 1.00 | EPHX1 (0.41) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL22081103 | 1.00 | EPHX1 (0.41) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL3805027 | 1.00 | EPHX1 (0.41) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL7524414 | 0.97 | — | — | |
| Acetic Acid SCHEMBL27595094 | 0.91 | EPHX1 (0.40) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL17670674 | 0.86 | — | — | |
| SCHEMBL24355253 | 0.75 | DPP4 (0.33) | — | |
| SCHEMBL24355538 | 0.75 | DPP4 (0.33) | — | |
| SCHEMBL13266401 | 0.75 | DPP4 (0.42) | — | |
| SCHEMBL8902005 | 0.74 | TP53 (0.41) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101558059-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-12-03 | — | — | CN | claimed |
| CN-101558059-A | Hepatitis C virus inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-10-14 | — | — | CN | claimed |
| CN-104447707-B | Hepatitis c virus inhibitors | 百时美施贵宝公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-104447707-A | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-03-25 | — | — | CN | disclosed |
| CN-101558059-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2014-12-03 | — | — | CN | disclosed |
| CN-102007122-B | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2013-09-04 | — | — | CN | disclosed |
| EP-2595975-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | Corning Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013018626-A1 | METHOD FOR PRODUCING ALPHA-KETOALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-02-07 | — | — | WO | disclosed |
| US-20120329865-A1 | MOLECULES RELATED hERG ION CHANNELS AND THE USE THEREOF | CORNING INCORPORATED | 2012-12-27 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| CN-1890238-A | Hydronopol derivatives as agonists on human ORL1 receptors | SOLVAY PHARM GMBH (DE) | 2007-01-03 | — | — | CN | disclosed |
| US-6284932-B1 | Method for producing alcohols containing cycloaliphatic groups | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-04 | — | — | US | disclosed |
| WO-2000023608-A1 | PREPARATION OF AMINO ALCOHOLS | DSM BIOTECH GMBH (DE) | 2000-04-27 | — | — | WO | disclosed |
| US-4507291-A | Arthropod repellents | ROHM AND HAAS COMPANY (US) | 1985-03-26 | — | — | US | disclosed |
| US-4405630-A | AZASPIRO COMPOUNDS | ROHM AND HAAS COMPANY (US) | 1983-09-20 | — | — | US | disclosed |
| US-4400512-A | INSECT REPELLENTS | ROHM AND HAAS COMPANY (US) | 1983-08-23 | — | — | US | disclosed |
| US-4374991-A | INSECT REPELLENTS | ROHM AND HAAS COMPANY (US) | 1983-02-22 | — | — | US | disclosed |
| US-4357471-A | INSECT REPELLENTS | ROHM AND HAAS COMPANY (US) | 1982-11-02 | — | — | US | disclosed |
| US-3940446-A | Dehydrogenation of alcohols | UNIVERSAL OIL PRODUCTS COMPANY (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | EPHX1 1619/4885TP53 3443/4885KDM4E 4643/4885 |
| US-20120329865-A1 | MOLECULES RELATED hERG ION CHANNELS AND THE USE THEREOF | KCNH2, KCNJ2, KCNH3 | EPHX1 1632/4885TP53 3030/4885KDM4E 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.